Skip to Main Content

Paper Details

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.
Advances in Therapy
1
2022
Author NameAffiliation
Stefan SchreiberChristian-Albrechts-University, University Hospital Schleswig-Holstein
  • 1 - 1

Datasets

Release 1.2